Does new-onset LBBB after TAVR worsen clinical outcomes (death, hospitalization, stroke, MI) at 1 year in patients without baseline intraventricular conduction delay?
New-onset LBBB after TAVR does not increase 1-year mortality or hard ischemic events, but increases the need for permanent pacemakers and blunts LVEF recovery.
Persistent, new-onset LBBB occurred in 10.5% of patients without intraventricular baseline conduction who underwent TAVR in the PARTNER experience. New LBBB was not associated with death, repeat hospitalization, stroke, or myocardial infarction at 1 year, but was associated with a higher rate of PPI and failure of left ventricular ejection fraction to improve.
Nazif et al. (2013) studied this question.